We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 55.00 | 45.00 | 65.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVRP
RNS Number : 3219T
Verona Pharma PLC
04 January 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) ----------------------------------------------------------------------------------------------- 1. Identity of the issuer or Verona Pharma plc the underlying issuer of existing shares to which voting rights are attached: (ii) ------------------------------------------------------------- -------------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): ----------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights -------------------------------------------------------------- ------------------------------- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached -------------------------------------------------------------- ------------------------------- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments -------------------------------------------------------------- ------------------------------- An event changing the breakdown of voting rights -------------------------------------------------------------- ------------------------------- Other (please specify): ------------------------------------------------------------ ------------------------------- 3. Full name of person(s) Wales Life Sciences Investment subject to the Fund LP notification obligation: (iii) ------------------------------------------------------------- -------------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) ------------------------------------------------------------- -------------------------------- 5. Date of the transaction 3 January 2017 and date on which the threshold is crossed or reached: (v) ------------------------------------------------------------- -------------------------------- 6. Date on which issuer 3 January 2017 notified: ------------------------------------------------------------- -------------------------------- 7. Threshold(s) that is/are crossed or reached: (vi, vii) 4.1% ------------------------------------------------------------- -------------------------------- 8. Notified details: ------------------------------------------------------------------------------------------------------------------------ A: Voting rights attached to shares (viii, ix) ------------------------------------------------------------------------------------------------------------------------ Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ----------- ---------------------------------- ----------------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights ----------- ---------------- ---------------- -------------- ---------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ----------- ------------ ------------ -------------- -------------- ------------ ------------ ----------- Ordinary 207,500,000 207,500,000 105,500,000 105,500,000 4.1% ---------------- ---------------- -------------- -------------- ------------ ------------ ----------- B: Qualifying Financial Instruments ------------------------------------------------------------------------------------------------------------------------ Resulting situation after the triggering transaction ------------------------------------------------------------------------------------------------------------------------ Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. --------------- -------------- -------------------------------- ------------------------------ --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ------------------------------------------------------------------------------------------------------------------------ Resulting situation after the triggering transaction ------------------------------------------------------------------------------------------------------------------------ Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) ------------- -------------- -------------- ---------------- ------------------------------ ----------------------- Nominal Delta ------------- -------------- -------------- ---------------- ------------------------------ ------------ --------- Total (A+B+C) ------------------------------------------------------------------------------------------------------------------------ Number of voting rights Percentage of voting rights ------------------------------------------------- --------------------------------------------------------------------- 105,500,000 4.1% ------------------------------------------------- --------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ----------------------------------------------------------------------------- Wales Life Sciences Investment Fund LP, as a stand-alone entity, previously held 8.1% of voting rights of Verona Pharma plc. After this disposal it holds 4.1% The Wales Life Sciences Investment Fund LP is managed by Arthurian Life Sciences Ltd. Arix Bioscience plc is the parent of Arthurian Life Sciences Ltd. Arix Bioscience plc separately holds 2.5% of the voting rights which remain unchanged. Proxy Voting: ----------------------------------------------------------------------------- 10. Name of the proxy holder: ------------------------------------------------------------- -------------- 11. Number of voting rights proxy holder will cease to hold: ------------------------------------------------------------- -------------- 12. Date on which proxy holder will cease to hold voting rights: ------------------------------------------------------------- -------------- 13. Additional information: ------------------------------------------------------------- -------------- 14. Contact name: Shafia Zahoor ------------------------------------------------------------- -------------- 15. Contact telephone number: 020-7290-1057 ------------------------------------------------------------- -------------- Note: Annex should only be submitted to the FCA not the issuer Annex: Notification of major interests in share A: Identity of the persons or legal entity subject to the notification obligation ---------------------------------------------------------------------- Full name Wales Life Sciences Investment (including legal form of Fund LP legal entities) ------------------------------------- ------------------------------- Contact address 20 Berkeley Square, London (registered office for legal W1J 6EQ entities) ------------------------------------- ------------------------------- Phone number & email 020-7290-1057 ------------------------------------- ------------------------------- Other useful information (at least legal representative for legal persons) ------------------------------------- ------------------------------- B: Identity of the notifier, if applicable ---------------------------------------------------------------------- Full name Shafia Zahoor
------------------------------------- ------------------------------- Contact address 20 Berkeley Square, London W1J 6EQ ------------------------------------- ------------------------------- Phone number & email 020-7290-1057 shafia@arixbioscience.com ------------------------------------- ------------------------------- Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) ------------------------------------- ------------------------------- C: Additional information ----------------------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUGUWGGUPMGUC
(END) Dow Jones Newswires
January 04, 2017 05:16 ET (10:16 GMT)
1 Year Verona Pharma Chart |
1 Month Verona Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions